source
- Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin LymphomaAlex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.onclive · 2mo ago↗ source
- Dr Sznol on Biomarkers of Response in Metastatic MelanomaMario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.onclive · 2mo ago↗ source
- Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipelineCentered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.BioPharma Dive